![]() | Hideaki YokooDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan. | Department of Human Pathology, Gunma University Graduate School ... |
KOL Resume for Hideaki Yokoo
Year | |
---|---|
2022 | Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan. |
2021 | Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, 371-8511, Maebashi, Gunma, Japan |
2020 | Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511, Japan |
2019 | Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa, 371-8511, Maebashi, Gunma, Japan |
2018 | Department of Human Pathology, Gunma University Graduate School of Medicine, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan |
2017 | Gunma University Graduate School of Medicine Department of Human Pathology Maebashi Japan |
2016 | Department of Human Pathology Gunma University Maebashi, Gunma |
2015 | Human Pathology, Gunma University Graduate School of Medicine; and. |
2014 | Department of Human Pathology, Gunma University, Maebashi, Japan |
2013 | From the Departments of Neurology (T.K., Masayoshi Tada, A. Koyama, H.N., M.A., A.I., M.N., T. Ikeuchi), Pathology (Mari Tada, K.O., H.T., A. Kakita), Molecular Neuroscience (O.O.), and Molecular Genetics, Brain Research Institute (T. Ikeuchi), Niigata University; Department of Neurology (Y.H.), Maebashi Red Cross Hospital; Department of Neurology (J.N.), Gyotoku General Hospital, Ichikawa; Department of Neurology (A.M., M.Y.), University of Fukui Hospital; Department of Neurology and Geriatrics (N.Y., T. Inuzuka), Gifu University Graduate School of Medicine; Department of Neurology (K. Ishihara, M.K.), Showa University School of Medicine, Tokyo; Department of Human Pathology (H.Y.), Gunma University Graduate School of Medicine, Maebashi; and the Department of Pathology and Applied Neurobiology (K. Itoh), Kyoto Prefectural University of Medicine, Japan. Department of Human Pathology, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan Human Pathology, and |
2012 | Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa, Maebashi, Gunma 371-8511, Japan |
2011 | Departments of Human Pathology |
2010 | * Assistant Professor, † Associate Professor, ‡ Graduate Student, ** Professor, Department of Anesthesiology, § Associate Professor, ∥ Professor, Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan. # Professor, Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan. Department of Human Pathology, Graduate School of Medicine, Gunma University |
2009 | Department of Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan 3Human Pathology, and Division of Pathology, Gunma University, |
2008 | 2Human Pathology, Gunma University, Graduate School of Medicine, Maebashi |
2007 | Pathology, Gunma University Graduate School of Medicine, Maebashishi, Gunma, Japan |
2006 | Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan |
2005 | First Department of Pathology, Gunma University School of Medicine, Maebashi, Japan |
2004 | From the Center for Neurodegenerative Disease Research (Drs. Cairns, Uryu, Lee, and Trojanowski), Department of Pathology and Laboratory Medicine and Institute on Aging, and Departments of Neurology (Dr. Grossman) and Psychiatry (Dr. Arnold), University of Pennsylvania School of Medicine, Philadelphia, PA, Department of Neuropathology (Dr. Bigio), Northwestern University Medical School, Chicago, IL, and Department of Pathology and Laboratory Medicine and Center for Neurodegenerative Disease (Dr. Gearing) and Department of Neurology (Drs. Juncos and Glass), Emory University School of Medicine, Atlanta, GA; Departments of Neurology (Dr. Burn) and Neuropathology (Drs. Jaros and Perry), Newcastle General Hospital, Newcastle-upon-Tyne, and Electron Microscope Division (S. Mosaheb and J.R. Thorpe), School of Life Sciences, University of Sussex, Brighton, UK; Laboratoire de Neuropathologie (Dr. Duyckaerts) and Federation de Neurologie (Drs. Stankoff and Pillon), Hôpital de la Salpêtrière, Paris, France; Department of Pathology (Dr. Skullerud), Rikshospitalet, Oslo, Norway; Institute of Neurological and Gerontological Sciences (Dr. Cruz-Sanchez), International University of Catalonia, Barcelona, Spain; Department of Pathology and Laboratory Medicine (Dr. Mackenzie), Vancouver General Hospital, British Columbia, Canada; and Department of Pathology (Drs. Yokoo and Nakazato), Gunma University School of Medicine, Maebashi, Japan. Department of Pathology, Gunma University School of Medicine, Gunma, Japan and International Agency for Research on Cancer, 69372 Lyon, France |
2003 | Department of Pathology, Gunma University School of Medicine, Maebashi 371-8511, Japan |
2002 | First Department of Pathology, Gunma University School of Medicine, Maebashi, Gunma, Japan Departments ofPathology and |
2001 | First Department of Pathology, International Agency for Research on Cancer (TW, HY, MY, PK, HO), Lyon, France and Department of Neurosurgery (YY), University Hospital, Zurich, Switzerland |
2000 | First Department of Pathology, Gunma University School of Medicine, Maebashi, |
1999 | First Department of Pathology, Gunma University School of Medicine, 3-39-22, Showa-machi, 371-8511, Maebashi, Gunma, Japan |
1998 | First Department of Pathology; Gunma University School of Medicine, Maebashi, Japan |
1997 | Department of Pathology, Gunma University School of Medicine, 3-39-22 Showamachi, Maebashi, Gunma 371, Japan Tel.: 81-272-20-7971; Fax: 81-272-20-7978, JP |
1996 | Department of Pathology, Gunma University School of Medicine |
1995 | Department of Pathology, Gunma University School of Medicine. |
1994 | Department of Pathology, Gunma University School of Medicine, 3-39-22 Showa-machi, 371, Maebashi, Gunma, Japan |
Hideaki Yokoo: Influence Statistics
Concept | World rank |
---|---|
glioblastoma k27m | #1 |
hist1h3b k27m mutation | #1 |
small uniform cells | #1 |
case presentationa 61yearold | #1 |
enveloping brain tissue | #1 |
antoni | #1 |
ogs rare | #1 |
transformation pxa | #1 |
mild peripheral enhancement | #1 |
conclusionsthe case | #1 |
tumor pxa | #1 |
cerebellar highgrade glioma | #1 |
malignant transformation pxa | #1 |
intraaxial hypointense mass | #1 |
hospital disorientation | #1 |
olig2 mib1 | #1 |
olig2 glioma | #1 |
gbm alterations | #1 |
twist zeb2 | #1 |
perivascular pseudorosettes | #1 |
increased twist | #1 |
twist zeb2 expression | #1 |
detectable gene deletion | #1 |
typical rmc cases | #1 |
worsening disorientation | #1 |
schwannoma intra | #1 |
numerous eosinophilic granules | #1 |
case rccump | #1 |
illustrative case k27m | #1 |
rccump rare variant | #1 |
snf5 baf47 | #1 |
cutaneous metastasis gliomas | #1 |
aggressive pediatric tumors | #1 |
twist zinc | #1 |
olig2positive tumor cells | #1 |
case capnon | #1 |
intracerebellar schwannomas | #1 |
gliomas rare | #1 |
reduced messengerrna expression | #1 |
remarkable degenerative | #1 |
nestin mib1 | #1 |
mp japan | #1 |
nestin focal expression | #1 |
pxa malignant | #1 |
schwannoma degenerative | #1 |
poor cellular processes | #1 |
lessons glioblastoma | #1 |
focal epithelioid cells | #2 |
degenerative structures schwannoma | #2 |
slowgrowing varieties | #2 |
Open the FULL List in Excel | |
Prominent publications by Hideaki Yokoo
Epithelioid glioblastoma (E-GBM) is a rare aggressive variant of IDH-wildtype glioblastoma newly recognized in the 2016 World Health Organization classification, composed predominantly of monotonous, patternless sheets of round cells with laterally positioned nuclei and plump eosinophilic cytoplasm. Approximately 50% of E-GBM harbor BRAF V600E, which is much less frequently found in other types of glioblastomas. Most E-GBM are recognized as primary/de novo lesions; however, several E-GBM ...
Known for Braf V600e | Tert Promoter Mutations | Epithelioid Glioblastoma | Homozygous Deletions | Kinase Inhibitor |
Abnormal neuronal aggregates of α-internexin and the three neurofilament (NF) subunits, NF-L, NF-M, and NF-H have recently been identified as the pathological hallmarks of neuronal intermediate filament (IF) inclusion disease (NIFID), a novel neurological disease of early onset with a variable clinical phenotype including frontotemporal dementia, pyramidal and extrapyramidal signs. α-Internexin, a class IV IF protein, a major component of inclusions in NIFID, has not previously been ...
Known for Neurodegenerative Diseases | Inclusion Disease | Neuronal Intermediate | Α Internexin | Major Component |
Central nervous system high-grade neuroepithelial tumors with BCOR alteration (CNS HGNET-BCOR) are a recently reported rare entity, identified as a small fraction of tumors previously institutionally diagnosed as so-called CNS primitive neuroectodermal tumors. Their genetic characteristic is a somatic internal tandem duplication in the 3' end of BCOR (BCOR ITD), which has also been found in clear cell sarcomas of the kidney (CCSK) and soft tissue undifferentiated round cell ...
Known for Soft Tissue | Neuroepithelial Tumor | Urcs Pmmti | Kidney Ccsk | Cns Hgnetbcor |
The aim of this study was to improve the neuropathologic recognition and provide criteria for the pathological diagnosis in the neurodegenerative diseases grouped as frontotemporal lobar degeneration (FTLD); revised criteria are proposed. Recent advances in molecular genetics, biochemistry, and neuropathology of FTLD prompted the Midwest Consortium for Frontotemporal Lobar Degeneration and experts at other centers to review and revise the existing neuropathologic diagnostic criteria for ...
Known for Ftd Ftld | Frontotemporal Lobar | Molecular Genetics | Corticobasal Degeneration | Pick Bodies |
The accurate depiction of both biologic and anatomic profiles of tumors has long been a challenge in PET imaging. An inflammation, which is innate in the carcinogenesis of oral squamous cell carcinoma (OSCC), frequently complicates the image analysis because of the limitations of (18)F-FDG and maximum standardized uptake values (SUV(max)). New PET parameters, metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as well as (18)F-fluoro-α-methyltyrosine ((18)F-FAMT), a ...
Known for Fdg Uptake | Cell Carcinoma | Mtv Tlg | Oral Squamous | Fluorodeoxyglucose F18 |
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low‐grade astrocytoma
[ PUBLICATION ]
Epithelioid glioblastoma (E-GBM) is a rare variant of glioblastoma (GBM), characterized by epithelioid cells with eosinophilic round cytoplasm devoid of stellate cytoplasmic processes. A number of studies have demonstrated that more than half of E-GBMs harbor a valine to glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (BRAF V600E). However, there are no previous reports on E-GBM with telomerase reverse transcriptase (TERT) promoter mutation in ...
Known for Epithelioid Glioblastoma | V600e Mutation | Tert Promoter | Gbm Braf | Rare Variant |
A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low‐grade diffuse astrocytoma
[ PUBLICATION ]
Epithelioid glioblastomas are one of the rarest histological variants of glioblastomas, which are not formally recognized by the World Health Organization (WHO) classification. Epithelioid glioblastomas usually occur as primary lesions, but there have been several reports of secondary epithelioid glioblastomas or epithelioid glioblastomas with pre- or co-existing lesions to date. The serine/threonine-protein kinase B-Raf (BRAF) V600E mutation has been found at a high frequency of 54% in ...
Known for Epithelioid Glioblastoma | Braf V600e Mutation | Diffuse Astrocytoma | Frontal Lobe | Low Grade |
α-Internexin Is Present in the Pathological Inclusions of Neuronal Intermediate Filament Inclusion Disease
[ PUBLICATION ]
Neuronal intermediate filament (IF) inclusion disease (NIFID) is a novel neurological disease of early onset with a variable clinical phenotype including frontotemporal dementia, pyramidal, and extrapyramidal signs. Pathologically, in affected areas, there is neuronal loss, astrocytosis, and neuronal intracytoplasmic aggregates of abnormal neuronal IFs that contain neither tau nor alpha-synuclein. Thus, to characterize the neuronal IF protein profile of inclusions in NIFID, ...
Known for Inclusion Disease | Intermediate Filament | Neuronal Proteins | Frontotemporal Dementia | Cases Nifid |
Analysis of Chromosome 19q13.42 Amplification in Embryonal Brain Tumors with Ependymoblastic Multilayered Rosettes
[ PUBLICATION ]
Recently, it was reported that ependymoblastoma and embryonal tumor with abundant neuropil and true rosettes (ETANTR) show 19q13.42 amplification at a high frequency, suggesting that these tumors may constitute a single entity. As ependymoblastic rosettes are the most prominent features in both subtypes, embryonal tumor with multilayered rosettes (ETMR) was proposed, for which 19q13.42 amplification represents a specific molecular hallmark. However, ependymoblastic rosettes are not ...
Known for Multilayered Rosettes | 19q1342 Amplification | Brain Tumors | Etantr Ependymoblastoma | Embryonal Tumor |
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease
[ PUBLICATION ]
BACKGROUND: Recently described neuronal intermediate filament inclusion disease (NIFID) shows considerable clinical heterogeneity.
OBJECTIVE: To assess the spectrum of the clinical and neuropathological features in 10 NIFID cases.
METHODS: Retrospective chart and comprehensive neuropathological review of these NIFID cases was conducted.
RESULTS: The mean age at onset was 40.8 (range 23 to 56) years, mean disease duration was 4.5 (range 2.7 to 13) years, and mean age at death was 45.3 ...
Known for Neuronal Intermediate | Inclusion Disease | Ftd Mnd | Nifid Cases | Spinal Cord |
Haploinsufficiency of CSF-1R and clinicopathologic characterization in patients with HDLS
[ PUBLICATION ]
OBJECTIVE: To clarify the genetic, clinicopathologic, and neuroimaging characteristics of patients with hereditary diffuse leukoencephalopathy with spheroids (HDLS) with the colony stimulating factor 1 receptor (CSF-1R) mutation.
METHODS: We performed molecular genetic analysis of CSF-1R in patients with HDLS. Detailed clinical and neuroimaging findings were retrospectively investigated. Five patients were examined neuropathologically.
RESULTS: We found 6 different CSF-1R mutations in 7 ...
Known for Patients Hdls | Messenger Receptors | White Matter | Csf1r Mutation | Corpus Callosum |
Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus.
[ PUBLICATION ]
Thymic size and density were studied in 23 untreated patients with Graves' disease and 38 control subjects using computed tomography. Both thymic size and density were higher in untreated patients with Graves' disease than in control subjects in the age-matched group. After treatment with antithyroid drugs, both thymic size and density were significantly reduced, with a concomitant decrease in thyrotropin receptor antibodies. PCR of human thymic cDNA using primers for human thyrotropin ...
Known for Thyrotropin Receptor | Human Thymus | Thymic Hyperplasia | Graves Disease | Computed Tomography |
Long-term Effect of Sciatic Nerve Block with Slow-release Lidocaine in a Rat Model of Postoperative Pain
[ PUBLICATION ]
BACKGROUND: Postoperative pain management is important for preventing perioperative complications. The authors examined the effectiveness of controlled-release lidocaine for sciatic nerve block in a rat model of postoperative pain.
METHODS: The authors created a novel slow-release lidocaine sheet (SRLS) with polylactic-coglycolic acid. In male Sprague-Dawley rats (postoperative pain model), the authors applied the SRLS, lidocaine alone, or polylactic-coglycolic acid (control) near the ...
Known for Postoperative Pain | Sciatic Nerve Block | Release Lidocaine | Paw Incision | Rat Model |
The overexpression of Twist and Slug and subsequent down-regulation of E-cadherin facilitate the acquirement of invasive growth properties in cancer cells. It is unclear which of these molecules are expressed in mesenchymal tumors in the central nervous system. Here, we investigated 10 cases each of hemangiopericytoma, solitary fibrous tumor, meningothelial, fibrous, angiomatous, and atypical meningiomas, and 5 cases of anaplastic meningioma for Slug, Twist, E-cadherin, and N-cadherin ...
Known for Slug Twist | Transcription Factors | Anaplastic Meningioma | Expression Cadherin | Biomarkers Tumor |
CXCL17 Expression by Tumor Cells Recruits CD11b+Gr1highF4/80− Cells and Promotes Tumor Progression
[ PUBLICATION ]
BACKGROUND: Chemokines are involved in multiple aspects of pathogenesis and cellular trafficking in tumorigenesis. In this study, we report that the latest member of the C-X-C-type chemokines, CXCL17 (DMC/VCC-1), recruits immature myeloid-derived cells and enhances early tumor progression.
METHODOLOGY/PRINCIPAL FINDINGS: CXCL17 was preferentially expressed in some aggressive types of gastrointestinal, breast, and lung cancer cells. CXCL17 expression did not impart NIH3T3 cells with ...
Known for Cxcl17 Expression | Tumor Cells | Mice Myeloid | Latest Member | Chemokines Cxc |
Key People For Malignant Transformation
Hideaki Yokoo:Expert Impact
Concepts for whichHideaki Yokoohas direct influence:Malignant transformation, Oligodendroglial tumors, Tumor cells, Autopsy case, Central nervous, Braf v600e, Postoperative pain, Epithelioid glioblastoma.
Hideaki Yokoo:KOL impact
Concepts related to the work of other authors for whichfor which Hideaki Yokoo has influence:Frontotemporal dementia, Central nervous, Alzheimer disease, Lobar degeneration, Amyotrophic lateral sclerosis, Spinal cord, Brain tumors.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |